Australia's most trusted
source of pharma news
Posted 21 June 2022 AM
The first human trial of a needle-free DNA Covid jab, developed by researchers at the University of Adelaide is set to start this week.
Enough doses of the vaccine have already been manufactured at BioCina's plant in the Adelaide suburb of Thebarton, which it bought from Pfizer late last year.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.